ASX:NEUPharmaceuticals
Why Neuren Pharmaceuticals (ASX:NEU) Is Up 6.3% After Record DAYBUE Royalties And Strong STIX Launch – And What's Next
In Q1 2026, Neuren Pharmaceuticals reported record net sales and more than 20% year-on-year royalty growth from Rett syndrome therapy DAYBUE, supported by Acadia Pharmaceuticals reaffirming full-year 2026 DAYBUE sales guidance of US$460–490 million.
A key driver was the successful US launch of DAYBUE STIX, a new powder formulation that has seen strong uptake and high caregiver satisfaction, while clinical programs in regions such as Japan and Europe continue to progress.
We’ll now examine...